PLRX vs. TNGX, EOLS, LBPH, ZNTL, ALXO, SAGE, ETNB, PRAX, OPK, and YMAB
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Tango Therapeutics (TNGX), Evolus (EOLS), Longboard Pharmaceuticals (LBPH), Zentalis Pharmaceuticals (ZNTL), ALX Oncology (ALXO), Sage Therapeutics (SAGE), 89bio (ETNB), Praxis Precision Medicines (PRAX), OPKO Health (OPK), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Pliant Therapeutics (NASDAQ:PLRX) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.
Pliant Therapeutics received 50 more outperform votes than Tango Therapeutics when rated by MarketBeat users. Likewise, 70.79% of users gave Pliant Therapeutics an outperform vote while only 56.52% of users gave Tango Therapeutics an outperform vote.
Pliant Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Pliant Therapeutics currently has a consensus target price of $45.67, indicating a potential upside of 230.68%. Tango Therapeutics has a consensus target price of $17.25, indicating a potential upside of 142.79%. Given Pliant Therapeutics' higher probable upside, equities analysts clearly believe Pliant Therapeutics is more favorable than Tango Therapeutics.
97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 5.6% of Pliant Therapeutics shares are held by company insiders. Comparatively, 6.2% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Pliant Therapeutics had 20 more articles in the media than Tango Therapeutics. MarketBeat recorded 32 mentions for Pliant Therapeutics and 12 mentions for Tango Therapeutics. Pliant Therapeutics' average media sentiment score of 0.09 beat Tango Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the media.
Tango Therapeutics has higher revenue and earnings than Pliant Therapeutics.
Pliant Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -278.55%. Pliant Therapeutics' return on equity of -33.93% beat Tango Therapeutics' return on equity.
Summary
Pliant Therapeutics beats Tango Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Pliant Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics Competitors List
Related Companies and Tools
